Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Horizon Therapeutics (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NEW YORK--(BUSINESS WIRE)--Horizon Therapeutics expands partnership with Medidata to speed clinical trial start-up and completion, using a broad range of technology solutions.

Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2020 financial results will be released on Wednesday, Feb. 24, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the

Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021

Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.

Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B

Horizon Pharma saw an improvement in its IBD SmartSelect Composite Rating Monday, from 94 to 96. The post Horizon Pharma Sees Rising Composite Rating To 96 appeared first on Investor's Business Daily.

Horizon Pharma Sees Rising Composite Rating To 96

Horizon Therapeutics PLC (NASDAQ: HZNP), a rare and rheumatic diseases drug company, announced a multibillion-dollar deal Monday to snap up Viela Bio Inc (NASDAQ: VIE). What Happened: Horizon said it has entered into a definitive agreement to acquire Viela for $53 per share in cash, which represents a fully diluted equity value of about $3.05 billion, or about $2.67 billion net of Viela's cash and cash equivalents.

Horizon Therapeutics To Buy Viela For $3.05B: What You Need To Know

Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the first quarter.

UPDATE: Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion

Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion

DUBLIN & GAITHERSBURG, Md.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio, Inc. common stock for $53.00 per share in cash, which represents a fully diluted equity value of approximately $3.05 billion, or approximately $2.67 billion net of Viela's cash and cash equivalents. As previously announce

Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio

Chegg

Etsy

Huntsman

Peloton

Block

Teladoc

Growth stocks are a great way to make money. Here are seven of the stronger names in the S&P 500's hottest sectors for investors to consider.

7 Growth Stocks in The S&P's Hottest Sectors That Are Primed to Explode

Biogen

Bio-Rad Laboratories

CVS Health

Moderna

Insulet

QuidelOrtho Corp

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Top Healthcare Stocks for February 2021

Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.

Horizon (HZNP) Provides Preliminary 2020 Financial Results

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials. “Amid the most challenging environment we have ever faced, we had a record year of performance, exceeding our full-year 2020 net sales and adjusted EBITDA guidance, driven by the significant outperformance of TEPEZZA and the strong second-half performance of KRYSTEXXA,” said Tim Walbert, chairman, president and chief executive officer,

Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (pegloticase injection) Trials

Horizon Therapeutics has morphed into a biotech star due to its new compound Tepezza. Tepezza is approved for the treatment of thyroid eye disease otherwise known as TED.

Horizon Therapeutics: Poised For Another Breakout

Acceleron Pharma

Health Care Select Sector SPDR Fund

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Top Healthcare Stocks for January 2021

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 39th Annual J.P. Morgan Healthcare Conference. Tim Walbert, chairman, president and chief executive officer, will present at 11:40 a.m. ET on Jan. 12, 2021. The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available following the event. About Horizon Horizo

Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandated COVID-19 vaccine production orders related to Operation Warp Speed that have dramatically restricted capacity available for the production of TEPEZZA at its drug product contract manufacturer, Catalent. Operation Warp Speed, per its authority provided through the Defense Production Act of 1950, recently

Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production

Gilead Sciences

Horizon Therapeutics PLC (NASDAQ:HZNP) and Gilead Sciences Inc (NASDAQ:GILD) are two contrasting stocks from the drug manufacturing industry, in my opinion. What they share is a price that has pulled back recent highs, but that doesn't necessarily make both of them bargains.

Horizon Therapeutics vs. Gilead

Amphastar Pharma

Amneal Pharmaceuticals

Phibro Animal Health

Supernus Pharmaceuticals

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Pharmaceutical Stocks for Q1 2021

LAKE FOREST, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has provided $500,000 in scholarships to Lake Forest College and created a $500,000 Horizon Therapeutics Endowed Scholarship Fund at Howard University. The scholarships at both institutions will be awarded to economically disadvantaged students and students of color. “Equity in education is a significant global issue and we feel it is important for companies and individuals who have the resources

Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Horizon Therapeutics (HZNP) Down 6.7% Since Last Earnings Report: Can It Rebound?

LAKE FOREST, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has provided $1.2 million in additional funding to U.S and international organizations to support COVID-19 relief efforts, including: The Chicago Community Trust, The Lake County Community Foundation, Silicon Valley Community Foundation, Greater Washington Community Foundation, Americares, ALONE, Family Carers Ireland, Enable Ireland and Toronto Foundation. Throughout 2020, Horizon has also provi

Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities

Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.

HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts

Halozyme Therapeutics

DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE® drug delivery technology for subcutaneous (SC) formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease, a serious, progressiv

Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology

Let's see if Horizon Therapeutics (HZNP) stock is a good choice for value-oriented investors right now from multiple angles.

Is Horizon Therapeutics (HZNP) a Worthy Stock Now?

News for Horizon Pharma Stock (HZNP)